Skip to main content

Table 2 Correlations between changes in GLP-1, NO, CIMT and other laboratory data following acarbose treatment

From: Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

 

Δfasting GLP-1

Δ2 h postprandial GLP-1

ΔNO

ΔNOS

 

R value

P value

R value

P value

R value

P value

R value

P value

â–³Weight

-0.143

0.506

0.014

0.950

0.024

0.911

0.121

0.574

â–³BMI

-0.128

0.550

0.027

0.899

0.038

0.861

0.138

0.519

â–³GHbA1c

-0.491

0.015

-0.636

0.001

-0.143

0.504

-0.149

0.488

â–³FPG

-0.185

0.388

-0.481

0.017

0.038

0.859

-0.108

0.617

â–³P2PG

-0.181

0.398

-0.110

0.608

0.241

0.256

0.007

0.973

△ln Insulin (0 h)

-0.176

0.411

0.145

0.498

0.285

0.177

0.363

0.081

△ln Insulin (2 h)

-0.035

0.871

0.084

0.696

0.135

0.528

0.079

0.713

â–³mean CIMT(mm)

-0.384

0.064

-0.628

0.001

-0.577

0.003

-0.314

0.135

â–³NO

0.245

0.249

0.452

0.026

-

-

0.449

0.028

â–³NOS

0.268

0.205

0.561

0.004

0.449

0.028

-

-

  1. Δ: The change of values following acarbose treatment; ln: natural logarithm -transformed values; BMI: body mass index; HbA1c: glycated haemoglobin A1c; FPG: fasting plasma glucose; P2PG: 2 hour postprandial plasma glucose; CIMT: carotid intima-media thickness; NO: nitric oxide; NOS: nitric oxide synthase.